ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1314 • 2019 ACR/ARP Annual Meeting

    Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative

    Matthew Harkey1, Lori Lyn Price 2, Kieran Reid 3, Grace Lo 4, Shao-Hsien Liu 5, Kate Lapane 1, Lucas Dantas 6, Timothy McAlindon 7 and Jeffrey Driban 7, 1University of Massachusetts Medical School, Worcester, 2Tufts Medical Center, Tufts University, Boston, MA, 3Tufts University, Boston, 4Center of Excellence Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, TX, 5University of Massachusetts Medical School, Worcester, MA, 6Tufts Medical Center, Boston, 7Tufts Medical Center, Boston, MA

    Background/Purpose: Despite an inter-play between objective physical function measures and various patient characteristics, no large-scale investigations in knee osteoarthritis (KOA) have explored complex interactions or…
  • Abstract Number: 1315 • 2019 ACR/ARP Annual Meeting

    Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study

    Jessica Maxwell1, Tuhina Neogi 2, Kay Crossley 3, Erin Macri 4, Daniel White 5, Ali Guermazi 6, Frank Roemer 7, Michael Nevitt 8, Beth Lewis 9, James Torner 10 and Joshua Stefanik 11, 1Northeastern University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3La Trobe University, Victoria, Australia, 4Erasmus MC, Rotterdam, Netherlands, 5University of Delaware, Newark, DE, 6Boston Medical Center, Boston, 7University of Erlangen-Nuremberg, Erlangen, Germany, 8University of California at San Francisco, San Francisco, CA, 9University of Alabama at Birmingham, Birmingham, AL, 10University of Iowa at Iowa City, Iowa City, 11Northeastern University, Boston

    Background/Purpose: Osteoarthritis (OA) of the knee is one of the most common causes of disability in the U.S. Often overlooked, OA specific to the patellofemoral…
  • Abstract Number: 1316 • 2019 ACR/ARP Annual Meeting

    Frail Patients Have Less Pain After Total Hip Replacement

    Lisa Mandl1, Charles Cornell 1, Michael Cross 1, Alejandro Gonzalez Della Valle 1, Mark Figgie 1, Seth Jerabek 1, Marianna Frey 2, John Roberts IV 3, Justin Do 3, Mayu Sasaki 3, Nathaniel Hupert 4, Jackie Finik 3 and Steven Magid 1, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, 2Hospital for Special Surgery, New York, NY, New York, 3Hospital for Special Surgery, New York, NY, New York, NY, 4Weill Cornell Medicine, New York, NY, New York, NY

    Background/Purpose: To determine whether frailty is associated with patient outcomes 1 year after total hip replacement (THR).Methods: Patients ≥65yo scheduled for elective primary THR for…
  • Abstract Number: 1317 • 2019 ACR/ARP Annual Meeting

    Frail Patients Have Worse Function After Total Knee Replacement

    Lisa Mandl1, Charles Cornell 1, Michael Cross 1, Alejandro Gonzalez Della Valle 1, Mark Figgie 1, Seth Jerabek 1, Marianna Frey 2, John Roberts IV 3, Justin Do 3, Mayu Sasaki 3, Nathaniel Hupert 4, Jackie Finik 3 and Steven Magid 1, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, 2Hospital for Special Surgery, New York, NY, New York, 3Hospital for Special Surgery, New York, NY, New York, NY, 4Weill Cornell Medicine, New York, NY, New York, NY

    Background/Purpose: To determine whether frailty is associated with patient outcomes 1 year after total knee replacement (TKR).Methods: Patients ≥65yo scheduled for elective primary TKR for…
  • Abstract Number: 1318 • 2019 ACR/ARP Annual Meeting

    In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms

    Jean-Pierre Pelletier1, Jean-Pierre Raynauld 2, Patrice Paiement 3, Marc Dorais 4 and Johanne Martel-Pelletier 5, 1University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 2Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 3ArthroLab Inc., Montreal, QC, Canada, 4StatSciences Inc., Notre-Dame-de-l'Île-Perrot, QC, Canada, 5University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada

    Background/Purpose: There was a need to ascertain in a clinical trial the comparative efficacy of diacerein, an IL-1 inhibitor, vis-à-vis celecoxib, a COX-2 inhibitor, in…
  • Abstract Number: 1319 • 2019 ACR/ARP Annual Meeting

    Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis

    stéphanie Ferrero1, marion louvois 1, Thomas Barnetche 2, Thao Pham 3, Véronique Breuil 1 and christian roux 4, 1University of Nice, nice, France, 2FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, 3Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, 4CHU Pasteur Nice, Nice, France

    Background/Purpose: Background: The development of knee's osteoarthritis after anterior cruciate ligament ACL injury is now widely recognized. The impact of surgical or rehabilitative management on…
  • Abstract Number: 1320 • 2019 ACR/ARP Annual Meeting

    Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort

    Pauline Baudart1, Anne-Christine Rat 2, Christian Marcelli 1 and Joséphine Bryère 3, 1CHU Caen, rheumatology department, Caen Normandie University, Caen, France, 2CHU Caen, rheumatology department, Caen Normandie University, Université de Lorraine, EA 4360 APEMAC, Caen, France, 3Inserm, university of Caen research U1086 Anticipe, Caen, France

    Background/Purpose: We analyzed the association between individual socio-economic status (SES) variables and clinical symptoms (function, pain and quality of life) in patients with symptomatic knee…
  • Abstract Number: 1321 • 2019 ACR/ARP Annual Meeting

    What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative

    Bright Dube1, Michael Bowes 2, Elizabeth Hensor 1, Sarah Kingsbury 3 and Philip G Conaghan 4, 1University of Leeds, LEEDS, England, United Kingdom, 2Imorphics, Manchester, England, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: 3D femur bone shape measured by statistical shape modelling (SSM) provides a responsive biomarker of knee OA. However it is unclear how the 3…
  • Abstract Number: 1322 • 2019 ACR/ARP Annual Meeting

    Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain

    Randall Stevens 1, Kimberly Guedes 1, Nilam Mistry 1, Paul Tiseo 2, Duncan Lascelles 3, Mario Mendoza1 and David Ball 4, 1Centrexion Therapeutics Corp, Boston, MA, 2Centrexion Therapeutics Corp, Boston, 3Translational Research in Pain, North Carolina State University, Raleigh, NC, 4MAC Clinical Research, Manchester, United Kingdom

    Background/Purpose: A double-blind, randomized, placebo-controlled trial (TRIUMPH; NCT02558439) with a single 1 mg intra-articular (IA) injection of CNTX-4975 (highly purified trans-capsaicin) into one knee for…
  • Abstract Number: 1323 • 2019 ACR/ARP Annual Meeting

    Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma

    Lilian SOLE1, Arthur Beck 1, Thomas Barnetche 2 and Pascale Vergne-Salle 3, 1CHU de Limoges, LIMOGES, France, 2CHU, Toulouse, France, 3CHU limoges, Limoges, France

    Background/Purpose: While there is growing evidences for the efficacy of platelet-rich plasma (PRP), there is still no standardized composition. There are 3 major types of…
  • Abstract Number: 1324 • 2019 ACR/ARP Annual Meeting

    Visceral Fat Deposition Associated with Pain in Osteoarthritis

    Shanshan Li 1, Nancy Desai2, Tuhina Neogi 3, Ann Schwartz 4, Lavalley Michael 1, Na Wang 3, Xianbang Sun 1, Michael Nevitt 5, Beth Lewis 6, Ali Guermazi 2, Frank Roemer 7, Neil Segal 8 and David Felson 9, 1Boston University, Boston, 2Boston Medical Center, Boston, 3Boston University School of Medicine, Boston, MA, 4University of California San Francisco, San Francisco, 5University of California at San Francisco, San Francisco, CA, 6University of Alabama at Birmingham, Birmingham, AL, 7University of Erlangen-Nuremberg, Erlangen, Germany, 8University of Kansas Medical Center, Kansas City, KS, 9Boston University School of Medicine, Department of Rheumatology, Boston

    Background/Purpose: Animal model studies have demonstrated the significant role of inflammation in the pathogenesis of osteoarthritis (OA) and of pain.  Visceral fat, rather than subcutaneous…
  • Abstract Number: 1325 • 2019 ACR/ARP Annual Meeting

    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA

    Agnès Lalande 1, Nadya Kuzniatsova-Mouchette 2, Florian Chassereau 1, Julia Geronimi 1, Staffan Larsson 3, Andre Struglics 3, Stefan Lohmander 3 and Maria Pueyo1, 1Institut de Recherches Internationales Servier, Suresnes, France, Suresnes, France, 2Institut de Recherches Internationales Servier, Suresnes, France, Suresnes, 3Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden, Lund, Sweden

    Background/Purpose: The disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5) is a key enzyme in OA (Verma P, et al. J Cell Biochem 2011;112:3507-14). In preclinical models…
  • Abstract Number: 1326 • 2019 ACR/ARP Annual Meeting

    Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

    Ismail Simsek 1, Chris Swearingen 1, Sarah Kennedy 1, Jeyanesh Tambiah 1, Yusuf Yazici2, Nancy Lane 3 and Marc C. Hochberg 4, 1Samumed, LLC, San Diego, 2Samumed, LLC, San Diego, CA, 3University of California at Davis Medical Center, Sacramento, CA, 4University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Recent concerns over osteoarthritis (OA) pharmacotherapy safety have led to revision of treatment guidelines and highlight the need for therapies with good safety profiles.…
  • Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting

    The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

    Yusuf Yazici1, Sarah Kennedy 2, Chris Swearingen 2 and Jeyanesh Tambiah 2, 1Samumed, LLC, San Diego, CA, 2Samumed, LLC, San Diego

    Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…
  • Abstract Number: 1328 • 2019 ACR/ARP Annual Meeting

    The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis

    Elise van Mulligen1, Angelique Weel 2, Martijn Kuijper 2, Mieke Hazes* 3, Annette van der Helm-van Mil 4 and Pascal de Jong 1, 1Erasmus MC, Rotterdam, Netherlands, 2Maasstad Hospital, Rotterdam, Netherlands, 3Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, 4LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: Previous studies have shown that it is possible to taper DMARDs in RA patients with an inactive disease, but this is accompanied with a…
  • « Previous Page
  • 1
  • …
  • 844
  • 845
  • 846
  • 847
  • 848
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology